BACKGROUND: The transforming growth factor-β (TGF-β) signaling pathway is involved in many aspects of tumorigenesis, including angiogenesis and metastasis. The authors evaluated this pathway in association with survival after a diagnosis of colon or rectal cancer. METHODS: The study included 1553 patients with colon cancer and 754 patients with rectal cancer who had incident first primary disease and were followed for a minimum of 7 years after diagnosis. Genetic variations were evaluated in the genes TGF-β1 (2 single nucleotide polymorphisms [SNPs]), TGF-β receptor 1 (TGF-βR1) (3 SNPs), smooth muscle actin/mothers against decapentaplegic homolog 1 (Smad1) (5 SNPs), Smad2 (4 SNPs), Smad3 (37 SNPs), Smad4 (2 SNPs), Smad7 (11 SNPs), bone morphogenetic protein 1 (BMP1) (11 SNPs), BMP2 (5 SNPs), BMP4 (3 SNPs), bone morphogenetic protein receptor 1A (BMPR1A) (9 SNPs), BMPR1B (21 SNPs), BMPR2 (11 SNPs), growth differentiation factor 10 (GDF10) (7 SNPs), Runt-related transcription factor 1 (RUNX1) (40 SNPs), RUNX2 (19 SNPs), RUNX3 (9 SNPs), eukaryotic translation initiation factor 4E (eiF4E) (3 SNPs), eukaryotic translation initiation factor 4E-binding protein 3 (eiF4EBP2) (2 SNPs), eiF4EBP3 (2 SNPs), and mitogen-activated protein kinase 1 (MAPK1) (6 SNPs). RESULTS: After adjusting for American Joint Committee on Cancer stage and tumor molecular phenotype, 12 genes and 18 SNPs were associated with survival in patients with colon cancer, and 7 genes and 15 tagSNPs were associated with survival after a diagnosis of rectal cancer. A summary score based on "at-risk" genotypes revealed a hazard rate ratio of 5.10 (95% confidence interval, 2.56-10.15) for the group with the greatest number of "at-risk" genotypes; for rectal cancer, the hazard rate ratio was 6.03 (95% confidence interval, 2.83-12.75). CONCLUSIONS: The current findings suggest that the presence of several higher risk alleles in the TGF-β signaling pathway increase the likelihood of dying after a diagnosis of colon or rectal cancer.
BACKGROUND: The transforming growth factor-β (TGF-β) signaling pathway is involved in many aspects of tumorigenesis, including angiogenesis and metastasis. The authors evaluated this pathway in association with survival after a diagnosis of colon or rectal cancer. METHODS: The study included 1553 patients with colon cancer and 754 patients with rectal cancer who had incident first primary disease and were followed for a minimum of 7 years after diagnosis. Genetic variations were evaluated in the genes TGF-β1 (2 single nucleotide polymorphisms [SNPs]), TGF-β receptor 1 (TGF-βR1) (3 SNPs), smooth muscle actin/mothers against decapentaplegic homolog 1 (Smad1) (5 SNPs), Smad2 (4 SNPs), Smad3 (37 SNPs), Smad4 (2 SNPs), Smad7 (11 SNPs), bone morphogenetic protein 1 (BMP1) (11 SNPs), BMP2 (5 SNPs), BMP4 (3 SNPs), bone morphogenetic protein receptor 1A (BMPR1A) (9 SNPs), BMPR1B (21 SNPs), BMPR2 (11 SNPs), growth differentiation factor 10 (GDF10) (7 SNPs), Runt-related transcription factor 1 (RUNX1) (40 SNPs), RUNX2 (19 SNPs), RUNX3 (9 SNPs), eukaryotic translation initiation factor 4E (eiF4E) (3 SNPs), eukaryotic translation initiation factor 4E-binding protein 3 (eiF4EBP2) (2 SNPs), eiF4EBP3 (2 SNPs), and mitogen-activated protein kinase 1 (MAPK1) (6 SNPs). RESULTS: After adjusting for American Joint Committee on Cancer stage and tumor molecular phenotype, 12 genes and 18 SNPs were associated with survival in patients with colon cancer, and 7 genes and 15 tagSNPs were associated with survival after a diagnosis of rectal cancer. A summary score based on "at-risk" genotypes revealed a hazard rate ratio of 5.10 (95% confidence interval, 2.56-10.15) for the group with the greatest number of "at-risk" genotypes; for rectal cancer, the hazard rate ratio was 6.03 (95% confidence interval, 2.83-12.75). CONCLUSIONS: The current findings suggest that the presence of several higher risk alleles in the TGF-β signaling pathway increase the likelihood of dying after a diagnosis of colon or rectal cancer.
Authors: W S Samowitz; K Curtin; D Schaffer; M Robertson; M Leppert; M L Slattery Journal: Cancer Epidemiol Biomarkers Prev Date: 2000-11 Impact factor: 4.254
Authors: Wade S Samowitz; Karen Curtin; Khe-ni Ma; Sandra Edwards; Donna Schaffer; Mark F Leppert; Martha L Slattery Journal: Int J Cancer Date: 2002-06-01 Impact factor: 7.396
Authors: Jean-Louis Boulay; Gabriele Mild; Adam Lowy; Juergen Reuter; Magali Lagrange; Luigi Terracciano; Urban Laffer; Richard Herrmann; Christoph Rochlitz Journal: Int J Cancer Date: 2003-04-20 Impact factor: 7.396
Authors: W S Samowitz; K Curtin; K N Ma; D Schaffer; L W Coleman; M Leppert; M L Slattery Journal: Cancer Epidemiol Biomarkers Prev Date: 2001-09 Impact factor: 4.254
Authors: Ewan R Cameron; Karen Blyth; Linda Hanlon; Anna Kilbey; Nancy Mackay; Monica Stewart; Anne Terry; Francois Vaillant; Sandy Wotton; James C Neil Journal: Blood Cells Mol Dis Date: 2003 Mar-Apr Impact factor: 3.039
Authors: Michael N Passarelli; Anna E Coghill; Carolyn M Hutter; Yingye Zheng; Karen W Makar; John D Potter; Polly A Newcomb Journal: Genes Chromosomes Cancer Date: 2011-08-24 Impact factor: 5.006
Authors: Martha L Slattery; Abbie Lundgreen; Roger K Wolff; Jennifer S Herrick; Bette J Caan Journal: Dis Colon Rectum Date: 2012-05 Impact factor: 4.585
Authors: Remond J A Fijneman; Rebecca A Anderson; Ethan Richards; Jieming Liu; Marianne Tijssen; Gerrit A Meijer; Janae Anderson; Annette Rod; Michael G O'Sullivan; Patricia M Scott; Robert T Cormier Journal: Cancer Sci Date: 2012-01-19 Impact factor: 6.716
Authors: Xabier Garcia-Albeniz; Hongmei Nan; Linda Valeri; Teppei Morikawa; Aya Kuchiba; Amanda I Phipps; Carolyn M Hutter; Ulrike Peters; Polly A Newcomb; Charles S Fuchs; Edward L Giovannucci; Shuji Ogino; Andrew T Chan Journal: Carcinogenesis Date: 2012-10-26 Impact factor: 4.944
Authors: Feng Chen; Ben Walder; Aaron W James; Donnalisa E Soofer; Chia Soo; Kang Ting; Xinli Zhang Journal: Int Orthop Date: 2012-07-14 Impact factor: 3.075